Chen Yong-Jian, Jin Wei-Dong, Yang Guang-Yu, Zhou Yong-Lie
Clinical Laboratory Center of Zhejiang Provincial People's Hospital, Hangzhou 310014, China.
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2011 Oct;25(5):381-3.
To evaluate the value of plasma ProGRP, CYFRA 21-1 and CEA in patients with lung cancer.
The levels of plasma ProGRP, CYFRA 21-1 and CEA were detected in 85 healthy control, 49 benign lung diseases and 143 lung neoplasms. The levels of ProGRP in the patients with SCLC was monitored.
The level of plasma ProGRP in SCLC (M 179.1 ng/ml) was significantly higher than adenocarcinoma (M 35.3 ng/ml), squamous-cell carcinoma (M 33.3 ng/ml), healthy control (M 35.6 ng/m) and benign lung diseases (M 33.3 ng/m), P < 0.001. The sensitivity and specificity for diagnosing SCLC by ProGRP were 60.6% and 95.0% respectively. In the effective treatment group, ProGRP reduced 45.9%, in the progression group, ProGRP increased 103.1%, P < 0.05. The level of CEA in the metastatic adenocarcinoma (M 10.22 ng/ml) was significantly higher than non-metastatic adenocarcinoma (M 3.85 ng/ml) and squamous cell carcinoma (M 2.56 ng/ml) (P < 0.01).
The plasma ProGRP is a good indicator for diagnosing and evaluating cure effect in SCLC; the high expression of CEA is related to the metastatic adenocarcinoma.
评估血浆胃泌素释放肽前体（ProGRP）、细胞角蛋白19片段（CYFRA 21-1）和癌胚抗原（CEA）在肺癌患者中的价值。
检测85例健康对照者、49例良性肺疾病患者和143例肺肿瘤患者血浆中ProGRP、CYFRA 21-1和CEA的水平。监测小细胞肺癌（SCLC）患者的ProGRP水平。
SCLC患者血浆ProGRP水平（中位数179.1 ng/ml）显著高于腺癌（中位数35.3 ng/ml）、鳞状细胞癌（中位数33.3 ng/ml）、健康对照者（中位数35.6 ng/ml）和良性肺疾病患者（中位数33.3 ng/ml），P<0.001。ProGRP诊断SCLC的敏感性和特异性分别为60.6%和95.0%。有效治疗组中，ProGRP降低了45.9%，进展组中，ProGRP升高了103.1%，P<0.05。转移性腺癌患者的CEA水平（中位数10.22 ng/ml）显著高于非转移性腺癌（中位数3.85 ng/ml）和鳞状细胞癌（中位数2.56 ng/ml）（P<0.01）。
血浆ProGRP是诊断和评估SCLC疗效的良好指标；CEA高表达与转移性腺癌有关。
